232 related articles for article (PubMed ID: 30359253)
1. An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline.
Sarocchi M; Bauckneht M; Arboscello E; Capitanio S; Marini C; Morbelli S; Miglino M; Congiu AG; Ghigliotti G; Balbi M; Brunelli C; Sambuceti G; Ameri P; Spallarossa P
J Transl Med; 2018 Oct; 16(1):295. PubMed ID: 30359253
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational
Bauckneht M; Ferrarazzo G; Fiz F; Morbelli S; Sarocchi M; Pastorino F; Ghidella A; Pomposelli E; Miglino M; Ameri P; Emionite L; Ticconi F; Arboscello E; Buschiazzo A; Massimelli EA; Fiordoro S; Borra A; Cossu V; Bozzano A; Ibatici A; Ponzoni M; Spallarossa P; Gallamini A; Bruzzi P; Sambuceti G; Marini C
J Nucl Med; 2017 Oct; 58(10):1638-1645. PubMed ID: 28646013
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of quantitative assessment of right ventricular glucose metabolism in patients with heart failure with reduced ejection fraction.
Tsai SY; Wu YW; Wang SY; Shiau YC; Chiu KM; Tsai HY; Lee CL; Hsu JC; Tu CM; Lin HH; Huang SH
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2601-2609. PubMed ID: 31410543
[TBL] [Abstract][Full Text] [Related]
4. Comparison of LVEF assessed by 2D echocardiography, gated blood pool SPECT, 99mTc tetrofosmin gated SPECT, and 18F-FDG gated PET with ERNV in patients with CAD and severe LV dysfunction.
Raja S; Mittal BR; Santhosh S; Bhattacharya A; Rohit MK
Nucl Med Commun; 2014 Nov; 35(11):1156-61. PubMed ID: 25144559
[TBL] [Abstract][Full Text] [Related]
5. An image processing tool for the detection of anthracycline-induced cardiotoxicity by evaluating the myocardial metabolic activity in [
Seiffert AP; Gómez-Grande A; Castro-Leal G; Rodríguez A; Palomino-Fernández D; Gómez EJ; Sánchez-González P; Bueno H
Int J Comput Assist Radiol Surg; 2022 Feb; 17(2):373-383. PubMed ID: 34698987
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT for evaluating systemic arterial inflammation induced by anthracycline-based chemotherapy of Hodgkin lymphoma: A retrospective cohort study.
Lawal IO; Orunmuyi AT; Popoola GO; Lengana T; Mokoala KMG; Ankrah AO; Sathekge MM
Medicine (Baltimore); 2020 Nov; 99(48):e23259. PubMed ID: 33235083
[TBL] [Abstract][Full Text] [Related]
7. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
8. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of myocardial glucose utilization in patients with left ventricular dysfunction by means of 18F-FDG dynamic positron tomography and three-compartment analysis.
Morita K; Katoh C; Yoshinaga K; Noriyasu K; Mabuchi M; Tsukamoto T; Kageyama H; Shiga T; Kuge Y; Tamaki N
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):806-12. PubMed ID: 15776232
[TBL] [Abstract][Full Text] [Related]
10. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
11. Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity.
Kim J; Cho SG; Kang SR; Yoo SW; Kwon SY; Min JJ; Bom HS; Song HC
J Nucl Cardiol; 2020 Dec; 27(6):2154-2163. PubMed ID: 30719656
[TBL] [Abstract][Full Text] [Related]
12. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.
Tseng D; Rachakonda LP; Su Z; Advani R; Horning S; Hoppe RT; Quon A; Graves EE; Loo BW; Tran PT
Radiat Oncol; 2012 Jan; 7():5. PubMed ID: 22260710
[TBL] [Abstract][Full Text] [Related]
13. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
14. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET.
Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Haberkorn U; Strauss LG
Clin Nucl Med; 2009 Sep; 34(9):576-84. PubMed ID: 19692817
[TBL] [Abstract][Full Text] [Related]
15. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
16. [Association between brain glucose metabolism and cardiac dysfunction in patients with ischemic heart disease undergoing (18)F-FDG PET/CT imaging].
Lu X; Nie BB; Yun MK; Zhu ZW; Xie XF; Mou TT; Mi HZ; Wei YX; Li X; Shan BC; Zhang XL
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Mar; 48(3):211-216. PubMed ID: 32234178
[No Abstract] [Full Text] [Related]
17. Chemotherapy-induced Cardiac18F-FDG Uptake in Patients with Lymphoma: An Early Metabolic Index of Cardiotoxicity?
Dourado MLC; Dompieri LT; Leitão GM; Mourato FA; Santos RGG; Almeida Filho PJ; Markman Filho B; Melo MDT; Brandão SCS
Arq Bras Cardiol; 2022; 118(6):1049-1058. PubMed ID: 35703659
[TBL] [Abstract][Full Text] [Related]
18. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
19. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
[TBL] [Abstract][Full Text] [Related]
20. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
